L-carnitine supplementation for rheumatoid arthritis patients
Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients
This study is testing if adding L-carnitine to the usual treatments can help adults with rheumatoid arthritis feel better and improve their joint health.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | German University in Cairo Academic / other |
| Locations | 1 site (Cairo, Demerdash) |
| Trial ID | NCT06753565 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of L-carnitine as an add-on therapy for patients with rheumatoid arthritis (RA) who are already receiving conventional disease-modifying anti-rheumatic drugs (DMARDs). It aims to improve patient outcomes by assessing the anti-inflammatory and antioxidant properties of L-carnitine. Eligible participants are adults aged 18-60 with active RA despite stable DMARD treatment for at least six months. The study will measure the impact of L-carnitine on disease activity and overall joint health.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-60 diagnosed with rheumatoid arthritis for at least six months who are currently on stable DMARD therapy but still experience active disease.
Not a fit: Patients who are pregnant, have liver or kidney dysfunction, or are taking medications that interact with carnitine may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for managing rheumatoid arthritis symptoms and improving patient quality of life.
How similar studies have performed: While the use of L-carnitine in other conditions has shown promise, this specific application in rheumatoid arthritis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 18-60 years old * diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months * enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study * active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2) * patient or legal representative should sign informed consent Exclusion Criteria: * pregnant or lactating female * patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST) * Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl) * Patients with any active infection or concurrent malignancy * patients with uncontrolled medical conditions or other rheumatic diseases * patients currently taking drugs that could interact with carnitine like: warfarin
Where this trial is running
Cairo, Demerdash
- Demerdash hospital — Cairo, Demerdash, Egypt (Recruiting)
Study contacts
- Study coordinator: Mariam Ehab, Master
- Email: mariam.ehab-azmy@guc.edu.eg
- Phone: +2001223360548
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.